Evidence map›Paper›PMID 38473402›Full record

ReviewCancers2024

Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.

Stefano Giuliani, Irene Paraboschi, Angus McNair, Myles Smith, Kenneth S Rankin, Daniel S Elson, Vinidh Paleri, Daniel Leff, Graeme Stasiuk, John Anderson and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Stefano GiulianiWellcome/EPSRC Centre for Interventional and Surgical Sciences, University College London, London W1W 7TY, UK.ORCID 0000-0002-4555-3093
Irene ParaboschiDepartment of Biomedical and Clinical Science, University of Milano, 20157 Milan, Italy.
Angus McNairNational Institute for Health Research Bristol Biomedical Research Centre, Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK.ORCID 0000-0002-2601-9258
Myles SmithThe Sarcoma, Melanoma and Rare Tumours Unit, The Royal Marsden Hospital, Institute Cancer of Research, London SW3 6JJ, UK.
Kenneth S RankinTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.ORCID 0000-0001-6302-0269
Daniel S ElsonHamlyn Centre for Robotic Surgery, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK.ORCID 0000-0002-5578-3941
Vinidh PaleriHead and Neck Unit, The Royal Marsden Hospitals, London SW3 6JJ, UK.
Daniel LeffDepartment of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK.
Graeme StasiukImaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, St Thomas' Hospital, London SE1 7EH, UK.
John AndersonCancer Section, Developmental Biology and Cancer Programme, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.
Precision Surgery Group at the NIHR Oncology Translational Research Collaboration
Great Ormond Street Hospital · GBImperial College London · GBRoyal Marsden Hospital · GBNorth Bristol NHS Trust · GBRoyal Victoria Infirmary · GBSt Thomas' Hospital · GBUniversity of Milan · IT

Funding

Medical Research Council MR/T005491/1
6 · The paper itself

Abstract

This study aims to review the status of the clinical use of monoclonal antibodies (mAbs) that have completed or are in ongoing clinical trials for targeted fluorescence-guided surgery (T-FGS) for the intraoperative identification of the tumor margins of extra-hematological solid tumors. For each of them, the targeted antigen, the mAb generic/commercial name and format, and clinical indications are presented, together with utility, doses, and the timing of administration. Based on the current scientific evidence in humans, the top three mAbs that could be prepared in a GMP-compliant bank ready to be delivered for surgical purposes are proposed to speed up the translation to the operating room and produce a few readily available "off-the-shelf" injectable fluorescent probes for safer and more effective solid tumor resection.

Indexed as

fluorophoresmonoclonal antibodiessolid malignanciessurgical oncologytargeted fluorescence-guided surgery

Identifiers

PMID38473402
PMCPMC10931077
OpenAlexW4392470466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.